Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jul 9;103(1):e209501.
doi: 10.1212/WNL.0000000000209501. Epub 2024 Jun 13.

Incidence and Types of Cardiac Arrhythmias in the Peri-Ictal Period in Patients Having a Generalized Convulsive Seizure

Affiliations
Observational Study

Incidence and Types of Cardiac Arrhythmias in the Peri-Ictal Period in Patients Having a Generalized Convulsive Seizure

Laura Vilella et al. Neurology. .

Abstract

Background and objectives: Generalized convulsive seizures (GCSs) are the main risk factor of sudden unexpected death in epilepsy (SUDEP), which is likely due to peri-ictal cardiorespiratory dysfunction. The incidence of GCS-induced cardiac arrhythmias, their relationship to seizure severity markers, and their role in SUDEP physiopathology are unknown. The aim of this study was to analyze the incidence of seizure-induced cardiac arrhythmias, their association with electroclinical features and seizure severity biomarkers, as well as their specific occurrences in SUDEP cases.

Methods: This is an observational, prospective, multicenter study of patients with epilepsy aged 18 years and older with recorded GCS during inpatient video-EEG monitoring for epilepsy evaluation. Exclusion criteria were status epilepticus and an obscured video recording. We analyzed semiologic and cardiorespiratory features through video-EEG (VEEG), electrocardiogram, thoracoabdominal bands, and pulse oximetry. We investigated the presence of bradycardia, asystole, supraventricular tachyarrhythmias (SVTs), premature atrial beats, premature ventricular beats, nonsustained ventricular tachycardia (NSVT), atrial fibrillation (Afib), ventricular fibrillation (VF), atrioventricular block (AVB), exaggerated sinus arrhythmia (ESA), and exaggerated sinus arrhythmia with bradycardia (ESAWB). A board-certified cardiac electrophysiologist diagnosed and classified the arrhythmia types. Bradycardia, asystole, SVT, NSVT, Afib, VF, AVB, and ESAWB were classified as arrhythmias of interest because these were of SUDEP pathophysiology value. The main outcome was the occurrence of seizure-induced arrhythmias of interest during inpatient VEEG monitoring. Moreover, yearly follow-up was conducted to identify SUDEP cases. Binary logistic generalized estimating equations were used to determine clinical-demographic and peri-ictal variables that were predictive of the presence of seizure-induced arrhythmias of interest. The z-score test for 2 population proportions was used to test whether the proportion of seizures and patients with postconvulsive ESAWB or bradycardia differed between SUDEP cases and survivors.

Results: This study includes data from 249 patients (mean age 37.2 ± 23.5 years, 55% female) who had 455 seizures. The most common arrhythmia was ESA, with an incidence of 137 of 382 seizures (35.9%) (106/224 patients [47.3%]). There were 50 of 352 seizure-induced arrhythmias of interest (14.2%) in 41 of 204 patients (20.1%). ESAWB was the commonest in 22 of 394 seizures (5.6%) (18/225 patients [8%]), followed by SVT in 18 of 397 seizures (4.5%) (17/228 patients [7.5%]). During follow-up (48.36 ± 31.34 months), 8 SUDEPs occurred. Seizure-induced bradycardia (3.8% vs 12.5%, z = -16.66, p < 0.01) and ESAWB (6.6% vs 25%; z = -3.03, p < 0.01) were over-represented in patients who later died of SUDEP. There was no association between arrhythmias of interest and seizure severity biomarkers (p > 0.05).

Discussion: Markers of seizure severity are not related to seizure-induced arrhythmias of interest, suggesting that other factors such as occult cardiac abnormalities may be relevant for their occurrence. Seizure-induced ESAWB and bradycardia were more frequent in SUDEP cases, although this observation was based on a very limited number of SUDEP patients. Further case-control studies are needed to evaluate the yield of arrhythmias of interest along with respiratory changes as potential SUDEP biomarkers.

PubMed Disclaimer

Conflict of interest statement

L. Vilella has received honoraria as a speaker from Jazz Pharmaceuticals, Angelini Pharma, Eisai, and UCB. C.Y. Miyake is funded by NHLBI K23HL136932. D. Friedman receives salary support for consulting and clinical trial–related activities performed on behalf of the Epilepsy Study Consortium, has received research funding (paid to the Epilepsy Study Consortium) from Biohaven, BioXcell, Cerevel, Cerebral, Epilex, Equilibre, Jannsen, Lundbeck, Praxis, Puretech, Neurocrine, SK Life Science, Supernus, UCB, and Xenon, has served as a paid consultant for Neurelis Pharmaceuticals, has received travel support from the Epilepsy Foundation, has received research support (unrelated to this study) from NINDS (R01 NS109367, R01 NS233102, R01NS123928, 1U44NS121562), NSF (A20 0089 S001), and CDC (6U48DP006396), holds equity interests in Neuroview Technology, and has received royalty income from Oxford University Press. M. Nei receives support as site investigator in clinical trials funded by UCB and Eisai and receives honoraria from MedLink Neurology. S. Schuele receives grant support from NIDCD, NIMH, NINDS, and NIH, is on the speaker bureau for Neurelis, SK Life Science, Jazz pharmaceuticals, and Sunovion, and has received compensation as consultant for Epilog and Monteris. R.M. Harper receives research support from UCLA Innovation funds (no personal income received for these activities), and holds patents for the use of devices to treat migraine and breathing disorders (patents owned by UCLA). O. Devinsky receives grant support from NINDS, NIMH, MURI, CDC, and NSF, has equity and/or has received compensation from the following companies: Tilray, Receptor Life Sciences, Qstate Biosciences, Hitch Biosciences, Tevard Biosciences, Regel Biosciences, Script Biosciences, Actio Biosciences, Empatica, SilverSpike, and California Cannabis Enterprises (CCE), has received consulting fees from Zogenix, Ultragenyx, BridgeBio, GeneMedicine, and Marinus, holds patents for the use of cannabidiol in treating neurologic disorders (patents owned by GW Pharmaceuticals), holds other patents in molecular biology, and is the managing partner of PhiFund Ventures. G.B. Richerson, Guo-Qiang Zhang, and S.D. Lhatoo are funded by NINDS/NIH. S.D. Lhatoo has served on the advisory board for UCB Pharma and LivaNova Inc. The other authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Similar articles

Cited by

References

    1. Sveinsson O, Andersson T, Mattsson P, Carlsson S, Tomson T. Clinical risk factors in SUDEP: a nationwide population-based case-control study. Neurology. 2020;94(4):e419-e429. doi: 10.1212/WNL.0000000000008741 - DOI - PMC - PubMed
    1. Verducci C, Hussain F, Donner E, et al. SUDEP in the North American SUDEP Registry: the full spectrum of epilepsies. Neurology. 2019;93(3):e227-e236. doi: 10.1212/WNL.0000000000007778 - DOI - PMC - PubMed
    1. Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2017;88(17):1674-1680. doi: 10.1212/WNL.0000000000003685 - DOI - PubMed
    1. Ryvlin P, Nashef L, Lhatoo SD, et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol. 2013;12(10):966-977. doi: 10.1016/S1474-4422(13)70214-X - DOI - PubMed
    1. Thijs RD, Ryvlin P, Surges R. Autonomic manifestations of epilepsy: emerging pathways to sudden death? Nat Rev Neurol. 2021;17(12):774-788. doi: 10.1038/s41582-021-00574-w - DOI - PubMed

Publication types

MeSH terms